论文部分内容阅读
目的:探讨小剂量利妥昔单抗联合龙花胶囊对成人血小板减少症患者促血小板生成素,肾功能水平及临床疗效的影响。方法:收集我院就收治的90例免疫性血小板减少症患者,随机分为实验组和对照组,每组45例。对照组患者给予小剂量利妥昔单抗治疗;实验组患者在对照组基础上使用龙花胶囊治疗。观察并比较两组患者血小板(PLT)计数、促血小板生成素(TPO)、肾功能水平以及临床治疗总有效率。结果:与治疗前相比,治疗后两组患者的PLT、TPO水平均升高,差异具有统计学意义(P<0.05);与治疗前相比,治疗后两组患者的肌酐(Scr)、尿素氮(BUN)水平均下降,差异具有统计学意义(P<0.05);与对照组相比,实验组患者PLT、TPO水平较低,Scr、BUN水平较高,差异具有统计学意义(P<0.05);与对照组相比,实验组患者临床治疗有效率较高,差异具有统计学意义(P<0.05)。结论:小剂量利妥昔单抗联合龙花胶囊能够升高血小板减少症患者血小板以及促血小板生成素水平,改善患者肾功能,临床疗效较好,提高了治疗效果。
Objective: To investigate the effect of low dose rituximab combined with Longhua capsule on thrombopoietin, renal function and clinical efficacy in patients with thrombocytopenia. Methods: Ninety patients with immune thrombocytopenia admitted to our hospital were randomly divided into experimental group and control group, with 45 cases in each group. Control group patients given low-dose rituximab treatment; experimental group patients in the control group on the basis of the use of Longhua capsule treatment. The platelet count (PLT), thrombopoietin (TPO), renal function and the total effective rate of clinical treatment in both groups were observed and compared. Results: The levels of PLT and TPO in both groups were significantly higher than those before treatment (P <0.05). Compared with before treatment, the levels of creatinine (Scr) Compared with the control group, the levels of PLT and TPO in the experimental group were lower, and the levels of Scr and BUN were higher in the experimental group (P <0.05), and the difference was statistically significant (P <0.05) <0.05). Compared with the control group, the clinical treatment efficiency of the experimental group was higher, the difference was statistically significant (P <0.05). Conclusion: Low-dose rituximab combined with Longhua Capsule can elevate platelet and thrombopoietin levels in patients with thrombocytopenia and improve renal function in patients. The clinical effect is better and the therapeutic effect is improved.